What Is PFAPA and Why Does it Matter?

Dennis J. Baumgardner

Follow this and additional works at: https://aurora.org/jpcrr

Part of the Diagnosis Commons, Immune System Diseases Commons, and the Pathological Conditions, Signs and Symptoms Commons

Recommended Citation

What Is PFAPA and Why Does it Matter?

Dennis J. Baumgardner, MD, Editor-in-Chief | Editorial

In this issue of *Journal of Patient-Centered Research and Reviews*, the article by Dr. Jillian Hudson discusses several evidence-based treatments for the common ambulatory care problem of recurrent aphthous stomatitis (RAS).\(^1\) RAS, as the author points out, is a highly prevalent disease with unknown etiology and no definitive treatment. Canker sores (aphthous stomatitis) are like headaches and heartburn, common conditions often disregarded unless one or a loved one is suffering with them. We at *Journal of Patient-Centered Research and Reviews* encourage further submissions on common health problems that disrupt patients’ daily activities. When I read Dr. Hudson’s article, I decided to take editorial prerogative and write about a condition related to RAS, and how the condition affects one patient in particular.

The condition is called PFAPA, and the patient is our son.

This uncommon disease, which involves recurrent oral aphthae, is the syndrome of periodic fever, aphthous stomatitis, pharyngitis and cervical lymphadenitis, typically abbreviated to PFAPA syndrome. Our special needs child has had approximately 75 bouts of this vexing disorder. At age 12, he began having episodes of fever, aphthous stomatitis, pharyngitis and cervical adenopathy as well as other nonspecific symptoms every 3 to 5 weeks. At first, understandably, it was a diagnostic dilemma, and these episodes were diagnosed as aphthous stomatitis plus pharyngitis or otitis media or sinusitis. Antibiotics were usually given. After several recurrences, there was sufficient clinical evidence to diagnose PFAPA. Having a diagnosis certainly reduced the anxiety around these episodes but did not diminish the disappointment and annoyance of unexpected missing of school, extracurricular activities or vacations.

The PFAPA syndrome was first proposed by Marshall and colleagues in 1987\(^2\) and its clinical features further described in the 1990s and early 2000s,\(^3-9\) culminating in two comprehensive reviews\(^10,11\) and one recently published large case series.\(^12\) These clinical features are summarized in Table 1. Malaise, irritability and fatigue may occur as part of a prodrome.\(^11\) Short episodes of illness recur regularly for several years, often “like clockwork” (typically at intervals between 3 and 6 weeks, depending on the individual), and alternate with healthy periods between the episodes. The classic diagnostic criteria used for PFAPA include regularly recurring fevers with onset at an early age (<5 years) and constitutional symptoms, in the absence of upper respiratory infection, with at least one of the following clinical signs: 1) aphthous stomatitis, 2) cervical lymphadenitis, 3) pharyngitis, 4) exclusion of cyclic neutropenia, and 5) completely asymptomatic interval between episodes accompanied by normal growth and development.\(^6\) While earlier publications suggested that symptom onset must occur by age 5 for diagnosis of PFAPA,\(^2,6\) onset of signs and symptoms otherwise consistent with PFAPA beyond the age of 5 was reported in 18 of 105 cases in a more recent case series.\(^8\) In addition, other studies have reported onset of PFAPA in older children\(^13\) and adults.\(^14\) Nonetheless, symptoms frequently begin before age 5 and continue through adolescence. There is sometimes a family history of PFAPA, especially in persistent cases.\(^11\)

The etiology of PFAPA is still unknown, but it is now considered one of the “autoinflammatory fever disorders.”\(^11\) A genetic component has been hypothesized\(^15\) but not yet established. Diverse ancestry among PFAPA patients was noted in one study.\(^8\) Other similar syndromes, such as familial Mediterranean fever, hyperimmunoglobulinemia

---

**Table 1. Features and symptoms of patients with periodic fever, aphthous stomatitis, pharyngitis and cervical lymphadenitis (PFAPA syndrome)**\(^8,10-12\)

<table>
<thead>
<tr>
<th>Feature/symptom</th>
<th>Range of frequency among patient populations analyzed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age of onset</td>
<td>2-5 years</td>
</tr>
<tr>
<td>Male(^5,8,9,22)</td>
<td>55-71%</td>
</tr>
<tr>
<td>Mean duration, each</td>
<td>3-5 days</td>
</tr>
<tr>
<td>Fever</td>
<td>Up to 100%</td>
</tr>
<tr>
<td>Fatigue (prodrome)(^9)</td>
<td>62%</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>65-100%</td>
</tr>
<tr>
<td>Cervical adenopathy</td>
<td>61-100%</td>
</tr>
<tr>
<td>Aphthous stomatitis</td>
<td>38-75%</td>
</tr>
<tr>
<td>Chills</td>
<td>61-80%</td>
</tr>
<tr>
<td>Headache</td>
<td>18-70%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>18-65%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>10-30%</td>
</tr>
<tr>
<td>Arthralgias</td>
<td>11-44%</td>
</tr>
<tr>
<td>Rhinorrhea</td>
<td>18-33%</td>
</tr>
<tr>
<td>Cough</td>
<td>20-28%</td>
</tr>
<tr>
<td>Rash</td>
<td>4-22%</td>
</tr>
</tbody>
</table>
Colchicine has shown variable response in small studies. It was not considered efficacious in a recent meta-analysis. However, it reportedly helps less than 30% of patients achieve remission and preventing future onset of PFAPA episodes. Treatment was purported to be effective in inducing remission and shortening the interval between episodes. Corticosteroids do not prevent further episodes and may make other symptoms slower to resolve. Unfortunately, the fever of PFAPA episodes within a few hours. However, has proved effective (84-99% response rate) for resolving the fever of PFAPA episodes within a few hours. However, other symptoms are slower to resolve. Unfortunately, corticosteroids do not prevent further episodes and may shorten the interval between episodes. Cimetidine treatment was purported to be effective in inducing remission and preventing future onset of PFAPA episodes, however, it reportedly helps less than 30% of patients and was not considered efficacious in a recent meta-analysis. Colchicine has shown variable response in small studies.

The natural history of PFAPA generally includes some degree of chronicity, however, episodes often get less intense and less frequent with age. Interestingly, some parents have noticed fewer PFAPA episodes in their children during summer months and that affected children seem to be less prone to common respiratory and gastrointestinal viral syndromes. Spontaneous resolution rates vary between 20% at a mean follow-up of 33 months and 49% (46/94) in those followed for more than 12 months, although 15 of these 46 had tonsillectomy. Our son, now 20 years old, has not enjoyed spontaneous resolution of this disorder, but he has experienced less intensity with many of the episodes, likely due in part to use of single-dose prednisone. We sometimes still forget that a day of lassitude likely indicates an impending “mouth sore.”

Regarding treatment, single-dose prednisone (1-2 mg/kg) has proved effective (84-99% response rate) for resolving the fever of PFAPA episodes within a few hours. However, other symptoms are slower to resolve. Unfortunately, corticosteroids do not prevent further episodes and may shorten the interval between episodes. Cimetidine treatment was purported to be effective in inducing remission and preventing future onset of PFAPA episodes, however, it reportedly helps less than 30% of patients and was not considered efficacious in a recent meta-analysis. Colchicine has shown variable response in small studies.

What is the difference between PFAPA and the subject of Dr. Hudson’s paper, RAS? The latter, taken apart from PFAPA, is probably a heterogeneous syndrome. Up to 40% of individuals in the United States have a history of RAS-like disease, though symptoms such as recurrent fever or pharyngitis are not observed. Initially, new-onset PFAPA episodes could be misdiagnosed as individuals with RAS having concurrent pharyngitis or other upper respiratory tract infections. This misdiagnosis could result in unnecessary antibiotic prescriptions. A population-based series in Norway of 46 children with PFAPA (calculated annual incidence rate of 2.3/10,000 children up to age 5 years) noted that 55% had received antibiotics during five or more PFAPA episodes. We studied 353 randomly selected cases of childhood aphthous stomatitis from our institution’s data warehouse (2002-2007); 47 of 353 (13%) were documented to be recurrent (at least two episodes in one year). Only two (0.6%) had PFAPA, consistent with this entity being rare in a community population. Antibiotics were prescribed in only 4% of all aphthous stomatitis cases without other diagnosis.

Lastly, despite it being an uncommon disease, PFAPA has become an area of active research. A study of 15 patients in Europe has detailed a variety of inflammatory markers that are increased during PFAPA febrile episodes only. The data suggest that monocyte production of interleukin (IL)-1 beta is dysregulated in patients with PFAPA. Similarly, a study of 18 patients showed polymorphonuclear neutrophils (PMNs), serum amylase A, and C-reactive protein are elevated in PFAPA patients when febrile, but not when afebrile. Also, PMNs from these patients have alterations in apoptosis, priming and intracellular oxidative bursts, especially during febrile attacks, when compared to febrile controls. A prospective study of 124 PFAPA patients in Israel revealed that 52% had Mediterranean fever gene
(MEFV) mutations. Compared to those without mutations, the patients with mutations, by an unknown mechanism, had shorter duration of febrile attacks and needed lower corticosteroid doses to abort attacks.26 Again, the underlying etiologies of the significant changes that lead to, or result from, febrile attacks in those with PFAPA is unclear.

The findings and discussion of a recently reported study of six patients is fascinating. The authors concluded from their data that febrile PFAPA episodes are the result of environmentally triggered disordered IL-1 and complement activation leading to chemokine release and retention of activated T-cells in peripheral tissue. Five patients were treated with a recombinant IL-1 receptor antagonist, with prompt favorable clinical and biomarker responses.27

In summary, PFAPA is a rare and vexing, but very interesting disease. Hopefully, the aforementioned recent basic and sentinel clinical research will translate to patient-friendly treatments for patients who suffer from this particular entity as well as for victims of related episodic fever disorders28 and perhaps other disorders of episodic immune dysregulation such as recurrent aphthous stomatitis.

Acknowledgment
The author thanks Michael H. Farrell, MD, of Aurora Health Care for manuscript suggestions.

References

© 2014 Aurora Health Care, Inc.